Understand the source comparison
FOXO4-DRI vs D+Q vs Navitoclax: Senolytic Mechanism Comparison
FOXO4-DRI Disrupts p53-FOXO4 protein complex, freeing p53 to induce apoptosis High. P53-FOXO4 complex is senescent-cell specific None observed in rodent studies at 5× effective dose Aging models, tissue-specific senescence, long-term treatment protocols Best c
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- FOXO4-DRI
- Disrupts p53-FOXO4 protein complex, freeing p53 to induce apoptosis
- High. P53-FOXO4 complex is senescent-cell specific
- None observed in rodent studies at 5× effective dose
- Aging models, tissue-specific senescence, long-term treatment protocols
- Best choice when mechanism specificity and repeated dosing are priorities
- Dasatinib + Quercetin (D+Q)
- Dasatinib inhibits ephrin receptor tyrosine kinases; quercetin induces oxidative stress
- Moderate. Both compounds affect healthy cells near senolytic threshold
- Gastrointestinal side effects, transient immunosuppression
- Preliminary senolytic screens, oral bioavailability studies
- Cost-effective for initial studies but requires careful dose optimization
- Navitoclax (ABT-263)
- Inhibits BCL-2 and BCL-xL anti-apoptotic proteins
- Moderate. BCL-xL inhibition affects platelets and other healthy cells
- Thrombocytopenia (platelet count reduction by 40–60%)
- Cancer-related senescence models, short-term single-dose experiments
- Effective but platelet toxicity limits long-term or repeated use